Literature DB >> 16930031

Beta2-amino acids in the design of conformationally homogeneous cyclo-peptide scaffolds.

Anna S Norgren1, Frank Büttner, Samran Prabpai, Palangpon Kongsaeree, Per I Arvidsson.   

Abstract

Herein, we report studies on the influence of chiral beta(2)-amino acids in the design of conformationally homogeneous cyclic tetrapeptide scaffolds. The cyclic alpha-tetrapeptide cyclo(-Phe-D-Pro-Lys-Phe-) (1) and its four mixed analogues, having one of the alpha-Phe replaced by either an (S)- or an (R)-beta(2)hPhe residue (i.e., cyclo(-(R)-beta(2)hPhe-D-Pro-Lys-Phe) (2a), cyclo(-(S)-beta(2)hPhe-D-Pro-Lys-Phe-) (2b), cyclo(-Phe-D-Pro-Lys-(R)-beta(2)hPhe-) (3a), and cyclo(-Phe-D-Pro-Lys-(R)-beta(2)hPhe-) (3b)), were all synthesized through solid-phase procedures followed by solution-phase cyclization. Initially, all five cyclo-peptides were analyzed by (1)H NMR spectroscopic studies in different solvents and at variable temperatures. Subsequently, a detailed 2D NMR spectroscopic analysis of three of the mixed peptides in water was performed, and the information thus extracted was used as restraints in a computational study on the peptides' conformational preference. An X-ray crystallographic study on the side chain-protected (Boc) 2a revealed the solid-state structure of this peptide. The results presented herein, together with previous literature data on beta(3)-amino acid residues, conclusively demonstrate the potential of beta-amino acids in the design of conformationally homogeneous cyclic peptides that are homologous to peptides with known applications in biomedicinal chemistry and as molecular receptors.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16930031     DOI: 10.1021/jo060854n

Source DB:  PubMed          Journal:  J Org Chem        ISSN: 0022-3263            Impact factor:   4.354


  8 in total

Review 1.  Cyclization-activated prodrugs.

Authors:  Paula Gomes; Nuno Vale; Rui Moreira
Journal:  Molecules       Date:  2007-11-12       Impact factor: 4.411

Review 2.  Medicinal significance of naturally occurring cyclotetrapeptides.

Authors:  Muna Ali Abdalla
Journal:  J Nat Med       Date:  2016-06-14       Impact factor: 2.343

3.  Design, synthesis, biological evaluation, and structural characterization of potent histone deacetylase inhibitors based on cyclic alpha/beta-tetrapeptide architectures.

Authors:  Ana Montero; John M Beierle; Christian A Olsen; M Reza Ghadiri
Journal:  J Am Chem Soc       Date:  2009-03-04       Impact factor: 15.419

4.  Discovery of potent and selective histone deacetylase inhibitors via focused combinatorial libraries of cyclic alpha3beta-tetrapeptides.

Authors:  Christian A Olsen; M Reza Ghadiri
Journal:  J Med Chem       Date:  2009-12-10       Impact factor: 7.446

5.  Conformationally homogeneous heterocyclic pseudotetrapeptides as three-dimensional scaffolds for rational drug design: receptor-selective somatostatin analogues.

Authors:  John M Beierle; W Seth Horne; Jan H van Maarseveen; Beatrice Waser; Jean Claude Reubi; M Reza Ghadiri
Journal:  Angew Chem Int Ed Engl       Date:  2009       Impact factor: 15.336

6.  Structural and Biofunctional Insights into the Cyclo(Pro-Pro-Phe-Phe-) Scaffold from Experimental and In Silico Studies: Melanoma and Beyond.

Authors:  Joanna Bojarska; Martin Breza; Milan Remko; Malgorzata Czyz; Anna Gajos-Michniewicz; Michał Zimecki; Krzysztof Kaczmarek; Izabela D Madura; Jakub M Wojciechowski; Wojciech M Wolf
Journal:  Int J Mol Sci       Date:  2022-06-28       Impact factor: 6.208

7.  The reactivity and conformational control of cyclic tetrapeptides derived from aziridine-containing amino acids.

Authors:  Benjamin K W Chung; Christopher J White; Conor C G Scully; Andrei K Yudin
Journal:  Chem Sci       Date:  2016-06-30       Impact factor: 9.825

8.  Efficient and regioselective synthesis of dihydroxy-substituted 2-aminocyclooctane-1-carboxylic acid and its bicyclic derivatives.

Authors:  İlknur Polat; Selçuk Eşsiz; Uğur Bozkaya; Emine Salamci
Journal:  Beilstein J Org Chem       Date:  2022-01-06       Impact factor: 2.883

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.